The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
Rigor acadêmico, estilo jornalístico
Todos os artigos de Pharmaceuticals
Exibindo 41 - 60 de 203 artigos
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
The Nigerian government must shore up efforts to stop the pollution of aquatic environments.
COVID has now claimed over 200,000 lives on the subcontinent, and the knock-on effects are likely to be substantial.
The FDA recalled commonly used heartburn and ulcer medication ranitidine in April 2020. But new research suggests less reason for alarm.
COVID-19 has resulted in higher than normal levels of medicine shortages. Here’s what to do if your local pharmacy is out of stock.
The world leader in generic medicines is facing stiff competition.
Details are sketchy. But it looks like people would still need to go through the legal system to get compensation. There are better ways.
Medical innovation is often accelerated in a time of crisis.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
As the United States risks prompting a bidding war for coronavirus drugs, can the world show solidarity over equitable access to medicines? And is remdesivir any use against COVID-19 anyway?
Preliminary results indicate dexamethasone could help treat severely ill patients in hospital with COVID-19. But it’s early days yet.
It usually takes 10 years for a new vaccine to complete clinical trials, but we’ve been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Early clinical trials into ginseng, rhubarb and rice paved the way for testing coronavirus treatments today.
The Covid-19 pandemic has laid bare Europe’s vulnerability to drug-supply disruption. Still, it remains by far the world leader in pharmaceutical products.
A lot depends on China and India sharing the products of their pharmacuetical manufacturing with the rest of the world.
Drug repurposing represents our only hope for the treatment of COVID-19 in the short term. But quick and rigorous trials need to be run to provide evidence these drugs work.
Nigeria’s reliance on drug importation is worrisome as COVID-19 pandemic rages.
Tax rates may be the same for big and small companies, but five charts show how things work out differently in practice.
Principais colaboradores
-
Professor and Director Academic Excellence, Macquarie University
-
Joel Lexchin é um amigo do The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Conjoint Clinical Associate Professor, Deakin University School of Medicine and Specialist Pain Medicine Physician, Deakin University
-
Lecturer Pharmacy Practice, University of Sydney
-
Pharmacist and PhD Candidate, University of Sydney
-
HERA Program Director - Health Workforce Optimisation Centre for the Business & Economics of Health, The University of Queensland
-
Assistant Professor, Bond University
-
PhD Candidate, Swinburne University of Technology
-
Research associate, University of Pretoria
-
Research Fellow, Stellenbosch University
-
Lecturer in Accounting & Management, Lancaster University
-
ARC Future Fellow, Australian National University
-
Purple House Medical Advisor. Honorary ANU., Australian National University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics, Macquarie University
